With the rate of major adverse cardiac events unchanged at 4.
Abbott announces positive results of bioresorbable vascular gadget at TCT conference Abbott today announced positive nine-month results from the first 45 patients signed up for the next stage of the ABSORB trial. At nine weeks, Abbott’s bioresorbable vascular scaffold demonstrated strong results that remained in keeping with the six-month data from the same 45-individual group, with the rate of major adverse cardiac events unchanged at 4.4 % no reports of blood clots cymbalta generic cost . These outcomes were presented during the Cardiovascular Study Foundation’s 22nd annual Transcatheter Cardiovascular Therapeutics conference in Washington, D.C. I am impressed with how consistent the BVS data have already been to date, as the nine-month data are compelling and supportive of previously positive results, stated John Ormiston, M.D., medical director at Mercy Hospital in Auckland, New Zealand, and co-principal investigator for the ABSORB trial.